Patent search ipc:"A61K31/52" Page 1

1.

发明申请
PHARMACEUTICAL RECTAL SUPPOSITORY COMPOSITIONS OF 6-THIOGUANINE, METHODS OF TREATMENT AND/OR METHODS OF MANUFACTURING 有权

公开(公告)号：US20250064816A1

公开(公告)日：2025-02-27

申请号：US18814130

申请日：2024-08-23

Applicant: Douglas Pharmaceuticals Ltd.

Inventor： Peter William Surman , Zhen Shi , Fergus Cameron Binnie , Christopher Ritchie , Yuefeng Long

IPC: A61K31/52 , A61K9/00 , A61K9/02 , A61K47/02 , A61K47/26 , A61K47/44 , A61P1/00

Abstract: Described is a rectal suppository. The rectal suppository comprises 6-thioguanine, at least one hard fat, and at least one surfactant. Further or alternatively, the rectal suppository comprises about 1 to 9 mg of 6-thioguanine. Further or alternatively, there is described a method of preventing, treating and/or managing inflammatory bowel disease in a subject. The method comprises administering a rectal suppository to the subject in need thereof. Further or alternatively, there is described a method of manufacturing a rectal suppository. The method comprises the steps of (a) heating a hard fat to become a liquid hard fat, (b) adding at least one surfactant to the liquid hard fat, (c) adding 6-thioguanine to the liquid hard fat, (d) forming the hard fat into a rectal suppository. Step (b) is optionally carried out before step (c) or after step (c).

2.

发明授权
Anti-cancer nuclear hormone receptor-targeting compounds 有权

公开(公告)号：US12208141B2

公开(公告)日：2025-01-28

申请号：US18472993

申请日：2023-09-22

Applicant: Nuvation Bio Inc.

Inventor： David Hung , Son Minh Pham , Sarvajit Chakravarty , Jiyun Chen , Jayakanth Kankanala , Jeremy D. Pettigrew , Anup Barde , Anjan Kumar Nayak

IPC: A61K47/55 , A61K9/00 , A61K31/438 , A61K31/4745 , A61K31/498 , A61K31/4985 , A61K31/502 , A61K31/5025 , A61K31/519 , A61K31/52 , A61K31/5377 , A61K31/55 , A61K47/68 , C07D401/12 , C07D401/14 , C07D403/12 , C07D471/04 , C07D471/06

Abstract: The disclosure relates to anti-cancer compounds derived from nuclear steroid receptor binders, to products containing the same, as well as to methods of their use and preparation.

3.

发明申请
NOVEL FORMULATION AND TREATMENT METHODS 有权

公开(公告)号：US20240423989A1

公开(公告)日：2024-12-26

申请号：US18823760

申请日：2024-09-04

Applicant: PRODRUGXTEND PTY LTD

Inventor： Timothy Florin , Amirali Popat , Siddharth Jambhrunkar

IPC: A61K31/52 , A61K9/00 , A61K9/08 , A61K9/20 , A61K9/28

Abstract: The invention relates to pharmaceutical compositions comprising 6-thioguanidine (6-TG) wherein the composition is formulated for release of 6-TG in the distal intestine. Methods for treating a disease or condition of the distal ileum that responds to 6-TG wherein the 6-TG is released in the distal intestine are also disclosed.

4.

发明授权
Uses of DPP IV inhibitors 有权

公开(公告)号：US12171767B2

公开(公告)日：2024-12-24

申请号：US17681997

申请日：2022-02-28

Applicant: Boehringer Ingelheim International GmbH

Inventor： Klaus Dugi , Frank Himmelsbach , Michael Mark

IPC: A61K31/522 , A61K31/155 , A61K31/197 , A61K31/4184 , A61K31/4985 , A61K31/5025 , A61K31/52 , A61K31/7048 , A61K45/06

Abstract: The specification describes the use of selected DPP IV inhibitors for the treatment of physiological functional disorders and for reducing the risk of the occurrence of such functional disorders in at-risk patient groups. In addition, the use of the above-mentioned DPP IV inhibitors in conjunction with other active substances is described, by means of which improved treatment outcomes can be achieved. These applications may be used to prepare corresponding medicaments.

5.

发明申请
EGFR PROTEOLYSIS TARGETING CHIMERIC MOLECULES AND ASSOCIATED METHODS OF USE 有权

公开(公告)号：US20240382599A1

公开(公告)日：2024-11-21

申请号：US18623722

申请日：2024-04-01

Applicant: Arvinas Operations, Inc. , Yale University

Inventor： Andrew P. Crew , Kurt Zimmermann , Jing Wang , Michael Berlin , Hanqing Dong , Alexey Ishchenko , Yimin Qian , Saul Jaime-Figueroa , George Burslem , Craig M. Crews

IPC: A61K47/54 , A61K31/427 , A61K31/454 , A61K31/496 , A61K31/506 , A61K31/517 , A61K31/519 , A61K31/52 , A61K31/55 , A61K31/551 , A61K38/07 , A61K45/06 , A61K47/55 , C07D471/04

Abstract: The present invention relates to bifunctional compounds, which find utility to degrade and (inhibit) TBK1. In particular, the present invention is directed to compounds, which contain on one end an E3 ubiquitin ligase binding moiety which binds to an E3 ubiquitin ligase and on the other end a moiety which binds TBK1 such that TBK1 is placed in proximity to the ubiquitin ligase to effect degradation (and inhibition) of TBK1. The present invention exhibits a broad range of pharmacological activities associated with compounds according to the present invention, consistent with the degradation/inhibition of TBK1.

6.

发明公开
METHODS AND PHARMACEUTICAL COMPOSITIONS FOR TREATING LYMPHOID MALIGNANCY 审中-公开

公开(公告)号：US20240358708A1

公开(公告)日：2024-10-31

申请号：US18649357

申请日：2024-04-29

Applicant: Thomas DIACOVO

Inventor： Thomas DIACOVO

IPC: A61K31/52 , A61K31/573 , A61K31/713 , C12N9/12 , C12N15/113 , C12Q1/6886 , G01N33/50 , G01N33/573

CPC classification number: A61K31/52 , A61K31/573 , A61K31/713 , C12N9/1205 , C12N15/1137 , C12Q1/6886 , C12Y207/01137 , C12Y207/01153 , G01N33/5041 , G01N33/573

Abstract: The present invention provides, inter alia, methods for treating, preventing, or ameliorating the effects of a lymphoid malignancy, such as those associated with a mutated phosphatase and tensin homolog (PTEN) gene, or T-cell acute lymphoblastic leukemia (T-ALL). These methods include administering to a subject an effective amount of a phosphoinositide 3-kinase-delta (PI3Kδ) inhibitor and a phosphoinositide 3-kinase-gamma (PI3Kγ) inhibitor. The present invention also provides pharmaceutical compositions for treating the effects of a lymphoid malignancy. This invention further provides a method for identifying a subject who may benefit from co-treatment with a PI3Kδ inhibitor and a PI3Kγ inhibitor. This method includes determining from a sample of the subject whether the subject has a mutated PTEN gene. Additionally, this invention provides methods for identifying a compound that has both PI3Kδ and PI3Kγ inhibitory activity.

7.

发明公开
A CYCLIN-DEPENDENT KINASE INHIBITOR 审中-公开

公开(公告)号：US20240352016A1

公开(公告)日：2024-10-24

申请号：US18682476

申请日：2022-08-10

Applicant: TAIZHOU EOC PHARMA CO., LTD.

Inventor： Lei Mo , Junkai Huang , Kai Li , Li Zhou , Xiaohui Hu

IPC: C07D473/16 , A61K31/52 , C07D519/00

CPC classification number: C07D473/16 , A61K31/52 , C07D519/00

Abstract: Provided are compounds as potent inhibitors of cyclin-dependent kinase (CDK), or pharmaceutically acceptable salts thereof. Corresponding compositions are also provided.